


PHARMACEUTICAL 2019

ARATANA THERAPEUTICS INC. Rank 47 of 371





PHARMACEUTICAL 2019



ARATANA THERAPEUTICS INC. Rank 47 of 371

The relative strengths and weaknesses of ARATANA THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ARATANA THERAPEUTICS INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 227% points. The greatest weakness of ARATANA THERAPEUTICS INC. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 50% points.

The company's Economic Capital Ratio, given in the ranking table, is 90%, being 421% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	58,127
Cost of Goods Sold	6,783
Intangible Assets	46,945
Liabilities, Current	5,557
Liabilities, Non-Current	57
Other Assets	671
Other Compr. Net Income	-473
Other Expenses	4,382
Other Liabilities	0
Other Net Income	-2,834
Property and Equipment	693
Research and Development	7,355
Revenues	35,412
Selling, General and Administrative Expense	28,780

Output Variable	Value in 1000 USD
Assets	106,436
Liabilities	5,614
Expenses	47,300
Stockholders Equity	100,822
Net Income	-14,722
Comprehensive Net Income	-14,958
Economic Capital Ratio	90%